Reimbursement authority NICE has backed the use of the two drugs as a first-line option for patients living with urothelial cancer (UC) – the most common form of bladder cancer – which has spread to ...

Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

"We are, of course, disappointed by the FDA's decision to not approve vatiquinone," said Matthew Klein, PTC's chief executive ...

Mindler has taken ownership of the UK company, which has been providing digitally delivered talking therapies to the NHS for ...

And while pharma marketing agencies are embracing AI like everyone else, most are using AI tools on a case-by-case basis to ...

Among the plans will be greater first-line use of SGLT-2 inhibitors or 'gliflozin' drugs, which are mainly used second-line ...

Shares in Viking Therapeutics have lost more than 40% of their value after it reported phase 2 results that showed that its ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

The decision to demerge the CSL Seqirus business into a separate ASX-listed company will allow it to "set an independent ...

Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...